Iloprost for additional anticoagulation in continuous renal replacement therapy - A pilot study

Renal Failure

Volumn 29, Issue 3, 2007, Pages 271-277

  Birnbaum, Jürgen ^a   Spies, Claudia D ^a   Klotz, Edda ^a   Hein, Ortrud Vargas ^a   Morgera, Stanislao ^a   Schink, Tania ^a   Ziemer, Sabine ^a   Grund, Mona S ^a   Saalmann, René ^a   Kox, Wolfgang J ^a   Lehmann, Christian ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Anticoagulation; Hemofiltration; Heparin; Iloprost

Indexed keywords

HEPARIN; ILOPROST;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG DOSE TITRATION; EXTRACORPOREAL CIRCULATION; FEMALE; HEMOFILTRATION; HUMAN; INTENSIVE CARE UNIT; MALE; MONOTHERAPY; PARTIAL THROMBOPLASTIN TIME; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTICOAGULANTS; BIOLOGICAL MARKERS; BLOOD COAGULATION; DRUG THERAPY, COMBINATION; FEMALE; HEMOFILTRATION; HEPARIN; HUMANS; ILOPROST; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PILOT PROJECTS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34248577496     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220601166222     Document Type: Article

References (25)

1. Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care. 2005;20(2):155-161.
2. Vargas Hein O, Kox WJ, Spies C. Anticoagulation in continuous renal replacement therapy. Contrib Nephrol. 2004;144:308-316.
3. Watson HR, Belcher G, Brierley JK, Dole WP. Iloprost in cardiopulmonary bypass procedures. Agents Actions Suppl. 1992;37:346-353.
4. Antoniou T, Kapetanakis EI, Theodoraki K, et al. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. Heart Surg Forum. 2002;5(4):354-357.
5. Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron. 1994;66(4):431-437.
6. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol. 1986;30(1):61-68.
7. Kennedy I, Coleman RA, Humphrey PP, Levy GP, Lumley P. Studies on the characterization of prostanoid receptors: a proposed classification. Prostaglandins. 1982;24(5):667-689.
8. Fiaccadori E, Maggiore U, Rotelli C, et al. Continuous hemofiltration in acute renal failure with prostacyclin as the sole antihemostatic agent. Intensive Care Med. 2002;28(5):586-593.
9. Lehmann C, Taymoorian K, Wauer H, Krausch D, Birnbaum J, Kox WJ. Effects of the stable prostacyclin analogue iloprost on the plasma disappearance rate of indocyanine green in human septic shock. 2000;26(10):1557-1560.
10. Korbut RA, Adamek-Guzik T, Madej J, Korbut R. Endothelial secretogogues and deformability of erythrocytes. J Physiol Pharmacol. 2002;53(4 Pt 1):655-665.
11. Muller B, Schmidtke M, Witt W. Adherence of leucocytes to electrically damaged venules in vivo. Effects of iloprost, PGE1, indomethacin, forskolin, BW 755 C, sulotroban, hirudin, and thrombocytopenia. Eicosanoids. 1988;1(1):13-17.
12. Lehmann C, Konig JP, Dettmann J, Birnbaum J, Kox WJ. Effects of iloprost, a stable prostacyclin analog, on intestinal leukocyte adherence and microvascular blood flow in rat experimental endotoxemia. 2001;29(7):1412-1416.
13. Vargas-Hein O, von-Heymann C, Lipps M, et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med. 2001;27(4):673-679.
14. Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med. 2000;26(11):1652-1657.
15. Baldwin I, Tan HK, Bridge N, Bellomo R. Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Ren Fail. 2002;24(6):839-848.
16. Asimakopoulos G. Systemic inflammation and cardiac surgery: an update. Perfusion. 2001;16(5):353-360.
17. Vargas Hein O, von Heymann C, Diehl T, et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Ren Fail. 2004;26(3):297-303.
18. Unger JK, Haltern C, Dohmen B, et al. Albumin and hydroxyethyl starch 130 kDa/0.4 improve filter clearance and hemocompatibility in hemo- and plasmafiltration - an in vitro study. Nephrol Dial Transplant. 2005;20(9):1922-1931.
19. Kozek-Langenecker SA. Anticoagulation with prostaglandins during extracorporeal circulation. Wien Klin Wochenschr. 1999;111(4):129-140.
20. Brierley JK, Hutchinson A. Prolongation of filter life in continuous arterio-venous hemodialysis. Intensive Care Med. 1991;17(3):187-188.
21. Kappa JR, Fisher CA, Todd B, et al. Intraoperative management of patients with heparin-induced thrombocytopenia. Ann Thorac Surg. 1990;49(5):714-722; discussion, 723.
22. Honkonen EL, Kaukinen L, Kaukinen S, Pehkonen EJ, Laippala P. Dopexamine unloads the impaired right ventricle better than iloprost, a prostacyclin analog, after coronary artery surgery. J Cardiothorac Vasc Anesth. 1998;12(6):647-653.
23. Opitz CF, Wensel R, Bettmann M, et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J. 2003;24(4):356-365.
24. Drinda S, Neumann T, Pohlmann G, et al. The response of skin perfusion and of rheological and immunological variables to intravenous prostanoid administration in Raynaud's phenomenon secondary to collagenosis. Vasa. 2005;34(4):243-249.
25. Czeslick EG, Simm A, Grond S, Silber RE, Sablotzki A. Inhibition of intracellular tumour necrosis factor (TNF)-alpha and interleukin (IL)-6 production in human monocytes by iloprost. Eur J Clin Invest. 2003;33(11):1013-1017.